All In Biotech

Investigational drug · Phase 2

TYK-01054

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor Malignancies, Malignant Mesothelioma (MM).

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "TYK-01054"

First trial start

2026

Jan 1, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TYK-01054", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Solid Tumor Malignancies
  • Malignant Mesothelioma (MM)

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "TYK-01054" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Solid Tumor Malignancies

  • FG-M108M108Phase 32 trials

    FutureGen Biopharmaceutical (Beijing) Co., Ltd · Claudin 18.2, Solid Tumor Malignancies, Pancreatic Cancer

  • FG-B901Phase 22 trials

    FutureGen Biopharmaceutical (Beijing) Co., Ltd · Claudin 18.2, Solid Tumor Malignancies, Solid Tumor

  • CP-383Phase 21 trial

    Tasca Therapeutics · Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC )

  • VTRU200Phase 21 trial

    Vitruviae · Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.